We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00401596
Recruitment Status : Completed
First Posted : November 20, 2006
Last Update Posted : March 19, 2014
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This was a multicenter, open label, randomized, controlled, safety trial in subjects aged 6-75 years with a diagnosis of moderate to severe, persistent asthma. A total of 1899 subjects were randomized (2:1) to either the active treatment group or the control group. Upon successful completion of the screening period (~2 weeks), each subject entered the 24 week study.

Condition or disease Intervention/treatment Phase
Asthma Drug: Xolair (omalizumab) Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1899 participants
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Subjects Already Treated With Other Therapies (ALTO)
Study Start Date : July 2000
Study Completion Date : July 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
Drug Information available for: Omalizumab
U.S. FDA Resources

Primary Outcome Measures :
  1. Incidence of all serious adverse events.

Secondary Outcome Measures :
  1. Incidence of all adverse events during the treatment phase of the study
  2. Incidence of protocol defined asthma exacerbation episodes (AEEs) during the treatment phase of the study
  3. Nocturnal symptoms as measured by the modified Inner City Asthma Study Morbidity Assessment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   6 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Documented physician diagnosis of moderate to severe, persistent asthma, defined in the National Heart, Lung, and Blood Institute (NHLBI) guidelines as FEV1 < 80% predicted for height, age, and sex or a history of FEV1 < 80%
  • Between 6 and 75 years old at the time of screening (Visit 1 [Week -2])
  • Current treatment with the following medications: Moderate doses of any inhaled steroid preparation on a daily basis for at least 30 days prior to screening; and/or oral steroids at a stable dose on a daily basis for at least 30 days prior to screening; and currently treated with at least one of the following drugs on a daily basis at a stable dose for at least 30 days prior to screening: long-acting β-adrenergic (salmeterol), leukotriene receptor antagonist (LTRA), xanthine derivatives, or sodium cromoglycate
  • Signed informed consent (in the case of a minor, consent must have been given by the child's parent or legal guardian)
  • Serum IgE level of ≥ 30 IU/mL and ≤ 1300 IU/mL and a body weight ≥ 20 kg and ≤ 150 kg and fell within the protocol-defined dosing table ranges
  • For females of childbearing potential, in the opinion of the investigator, use of an effective method of contraception to prevent pregnancy and agreement to continue to practice an acceptable method of contraception for the duration of their participation in the study
  • Willingness to participate fully for the duration of the study

Exclusion Criteria:

  • Current active AEE defined as requiring initiation or increase in oral steroid dose or treatment with at least a doubling of inhaled steroid dose
  • Thrombocytopenia as evidenced by platelets < 100,000/uL
  • Pregnancy or lactation
  • Previous randomization in this study
  • Use of any experimental drug within 30 days prior to study screening
  • Known hypersensitivity to any ingredients of Xolair, including excipients (sucrose, histidine, polysorbate 20)
  • Diagnosis of aspirin or nonsteroidal anti-inflammatory drug-induced asthma
  • Active lung disease other than asthma (e.g., chronic bronchitis, emphysema, cystic fibrosis, chronic obstructive pulmonary disease)
  • History of smoking within 2 years of the study screening visit or history of smoking ≥ 10 pack years
  • Significant systemic disease (e.g., infection, hematologic, renal, hepatic, coronary heart disease or other cardiovascular diseases, endocrinologic or gastrointestinal disease) within the previous 3 months
  • History of neoplasia
  • History of noncompliance to medical regimens
  • Any systemic condition requiring regular administration of immunoglobulin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00401596

Sponsors and Collaborators
Genentech, Inc.
Study Director: Yamo Deniz, M.D. Genentech, Inc.

Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT00401596     History of Changes
Other Study ID Numbers: Q2143g
First Posted: November 20, 2006    Key Record Dates
Last Update Posted: March 19, 2014
Last Verified: March 2014

Keywords provided by Genentech, Inc.:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Allergic Agents
Anti-Asthmatic Agents
Respiratory System Agents